Navigation Links
Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Date:8/23/2007

coplatin in an ongoing Phase 1 clinical trial as a first-line treatment for metastatic colorectal cancer and in an ongoing Phase 2 trial in combination with docetaxel (Taxotere(R)) and prednisone in patients with metastatic hormone-refractory prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Intravenous picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancer, and oral picoplatin is in a clinical trial in solid tumors. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's operations and financial condition, business objectives and strategic goals, drug development plans, and the efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of t
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MOUNTAIN VIEW, Calif., July 31, 2014 IRIDEX Corporation ... the second quarter and six months ended June 28, 2014.  ... quarter of 2014, up 15% from $9.2 million in the ... the first quarter of 2014. Revenues for the first six ... million in the first six months of last year. ...
(Date:7/31/2014)... SAN DIEGO, July 31, 2014 Tandem Diabetes Care®, ... and manufacturer of the t:slim® Insulin Pump, today reported its ... In comparing the second quarter of 2014 to ... percent to $10.3 million from $5.5 million , t:slim ... pumps In comparing six months ended June 30, ...
(Date:7/31/2014)... 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... the quarter ended June 30, 2014. Financial Results ... Revenue Total revenue for the quarter ended June 30, ... quarter ended June 30, 2013 primarily due to IMBRUVICA ® ... Total revenue for the six months ended June 30, ...
Breaking Medicine Technology:IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25
...   OncoSec Medical Incorporated (OTCBB:ONCS), which is ... therapies to treat solid tumor cancers, today announced ... company,s Phase II Merkel cell carcinoma clinical trial, ... The Journal Newspaper.    (Logo: ...
... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ("AcelRx"), ... commercialization of innovative therapies for the treatment of acute ... in a Phase 3 study for ARX-01, the Sufentanil ... This first ARX-01 Phase 3 study is a randomized, ...
Cached Medicine Technology:OncoSec's OMS ElectroImmunotherapy Technology Platform and its Ongoing Phase II Merkel Cell Carcinoma Clinical Trial Featured in Seattle Newspaper 2OncoSec's OMS ElectroImmunotherapy Technology Platform and its Ongoing Phase II Merkel Cell Carcinoma Clinical Trial Featured in Seattle Newspaper 3OncoSec's OMS ElectroImmunotherapy Technology Platform and its Ongoing Phase II Merkel Cell Carcinoma Clinical Trial Featured in Seattle Newspaper 4AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain 2AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain 3AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain 4AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain 5
(Date:8/1/2014)... in St. Louis helps explain why brain tumors occur ... than similar tumors in females. For example, glioblastomas, the ... often in males, who suffer greater cognitive impairments than ... researchers found that retinoblastoma protein (RB), a protein known ... male brain cells than in female brain cells. , ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, 2014 (HealthDay News) ... have significantly less endurance than those who weigh less, a new ... were obese, half were of normal weight -- people who were ... Obesity also was associated with less strength, increased discomfort and ... to 65 years of age -- neither improved nor reduced a ...
(Date:8/1/2014)... -- Almost 140 people die every year in ... States. But there are several simple ways ... prevention coordinator at Cincinnati Children,s Hospital Medical Center,s ... center news release. "As families begin to ... for parents and children to go over school ...
(Date:8/1/2014)... Summer is here, and with it comes the ... and they can be a pain for dogs. Animal Emergency ... their customers get rid of ticks and prevent them completely. ... the summer, which is why they are so active during ... woodland areas and carry a number of diseases, including lyme ...
(Date:8/1/2014)... and transgender individuals who want to conceive a child ... heterosexual and cisgendered peers, such as reduced fertility, but ... legal challenges to become parents. A comprehensive review of ... presented in the article " LGBT Assisted Reproduction: Current ... LGBT Health , a peer-reviewed journal from Mary ...
Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:Expert Offers School Bus Safety Tips 2Health News:Tis the Season for Tick Prevention 2Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2
... subjects that they were actually losing weight.,// ,Researchers belonging ... believe that they were losing weight when in reality they ... which gave the illusion that their hands were moving inward. ... creating a new body image. , The stimulators used ...
... to new research, elderly heart failure patients in United ... but lose that advantage over time.// ,Their study ... of Internal Medicine. ,Heart failure is the most ... older in both countries. ,The authors compared process ...
... have made the task of hasseled mothers easier by revealing ... foods even when in the womb. Making the task of ... they want their babies to when they are pregnant. ... of amniotic fluid a day and it is believed that ...
... conducted by researchers at University of Texas Southwestern Medical ... problem //faced by diabetics by increasing their blood pressure. ... professor and chief of the division of nutrition and ... a high-carb diet on blood pressure with a diet ...
... that the libido of a patient may be affected ... The secretion and creation of testosterone triggered by some ... of the patient. ,For most epileptics, however, treating ... a sensible approach, experts say. ,If no drugs ...
... to a latest survey, there is a steady decline in ... // . ,The findings were presented at the ... month by researchers from Cancer Research UK and the UK ... while cancer incidence rates have remained stable, there has been ...
Cached Medicine News:Health News:Disparity In Survival Rates In US and Canadian heart Patients 2Health News:Carbohydrate-rich Diet In Diabetes Raises Blood Pressure 2
The Duran Flexible Annuloplasty System encompasses both performance and practicality....
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,407-0) or contact custom...
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
... The new Finnpipette Focus from Thermo Labsystems ... uncompromising performance. Advanced features such as ... fine volume adjustment on microvolumes help to ... single channel pipettes. The new interchangeable handle ...
Medicine Products: